Prime Medicine, Inc.
PRME
$4.04
$0.308.02%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -33.39% | 944.50% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -33.39% | 944.50% | |||
| Cost of Revenue | -91.63% | -15.46% | |||
| Gross Profit | 95.61% | 20.46% | |||
| SG&A Expenses | 7.99% | -12.77% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 16.03% | -14.76% | |||
| Operating Income | -18.47% | 18.46% | |||
| Income Before Tax | -22.74% | 19.50% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -22.74% | 19.50% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -22.74% | 19.50% | |||
| EBIT | -18.47% | 18.46% | |||
| EBITDA | -19.26% | 19.31% | |||
| EPS Basic | -22.79% | 26.36% | |||
| Normalized Basic EPS | -20.04% | 27.23% | |||
| EPS Diluted | -22.79% | 26.36% | |||
| Normalized Diluted EPS | -20.04% | 27.23% | |||
| Average Basic Shares Outstanding | -0.03% | 9.32% | |||
| Average Diluted Shares Outstanding | -0.03% | 9.32% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||